Company intelligence / Profile preview

Bloodmates

Seoul, Seoul, South Korea

Ownership: Private
Employees: ~20
Development stage: Other

Overview

BloodMates is a South Korean biotechnology company specializing in liquid biopsy technologies for early cancer detection and monitoring. The company's core platform focuses on the high-purity isolation and analysis of circulating tumor cells (CTCs) from blood samples. By leveraging advanced microfluidic and molecular diagnostic techniques, BloodMates aims to provide non-invasive, precise diagnostic solutions that improve patient outcomes through better cancer management. Their technology is designed to support personalized medicine by enabling real-time monitoring of tumor progression and treatment response.

Therapeutic areas: Oncology
Modalities: Liquid biopsyDiagnostic platformDevice
Industry: Molecular Diagnostics

Partnerships

Yonsei University Health System

Beyond the preview

Go deeper on Bloodmates.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bloodmates.

Explore the full profile